TABLE 1.

Demographical and clinical variables between two clusters.

Characteristics	Cluster 1 (n = 161)	Cluster 2 (n = 56)	P-values
Age, years	73.9 ± 6.82	77.8 ± 6.58	<0.001
Education, years	15.7 ± 2.8	15.9 ± 3.47	0.66
Female gender, n (%)	72 (44.7)	15 (26.8)	0.018
APOE4 carriers, n (%)	70 (43.5)	22 (39.3)	0.58
MCI diagnosis, n (%)	98 (60.9)	32 (57.1)	0.62
MMSE scores	27.8 ± 1.86	27.7 ± 1.82	0.81
RAVLT total learning score	35.5 ± 10.9	34.1 ± 10.5	0.38
HpVR	4.39 ± 0.75	4.24 ± 0.66	0.22
CSF Aβ42 levels, pg/ml	184 ± 55.7	189 ± 58.4	0.56
CSF t-tau levels, pg/ml	81.7 ± 45.4	103 ± 67.7	0.03
CSF p-tau levels, pg/ml	29 ± 15.2	35.2 ± 21.5	0.050
CSF inflammatory markers, pg/ml
TNF-α	1.62 ± 0.427	2.74 ± 3.48	0.02
TNF-R1	816 ± 166	1038 ± 315	<0.001
TNF-R2	961 ± 195	1372 ± 725	<0.001
TGF-β1	93.7 ± 26.2	144 ± 51	<0.001
TGF-β2	162 ± 52.7	162 ± 38.4	0.995
TGF-β3	2.81 ± 0.517	32.3 ± 45.5	<0.001
IL-21	11.1 ± 11.6	13.2 ± 15.9	0.37
IL-6	4.19 ± 2.11	8.4 ± 9.37	0.002
IL-7	1.11 ± 0.746	1.76 ± 3.48	0.17

MCI, mild cognitive impairment; MMSE, mini-mental state examination; RAVLT, Rey Auditory Verbal Learning Test; HpVR, hippocampal/intracranial volumes ratio; TNF- α, Tumor Necrosis Factor- α; TNF-R1, Tumor Necrosis Factor Receptor 1; TNF-R2, Tumor Necrosis Factor Receptor 2; TGF-β1, Transforming Growth Factor-β1; TGF-β2, Transforming Growth Factor-β2; TGF-β3, Transforming Growth Factor-β3; IL, Interleukin.